A Study on the Efficacy and Safety of Gabapentin in the Treatment of Patients With Painful Diabetic Neuropathy
Status:
Completed
Trial end date:
2004-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study was to evaluate the efficacy, safety, and tolerability of
gabapentin for the treatment of patients with painful diabetic neuropathy. The quality of
life of all treated patients was also assessed.
Phase:
Phase 4
Details
Lead Sponsor:
Pfizer Pfizer's Upjohn has merged with Mylan to form Viatris Inc.